Pharmaceutical

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihood of Approval

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Peritoneal Cancer.

Dec 24, 2023 - 18:00
Enzalutamide is under clinical development by Pfizer and currently in Phase II for Peritoneal Cancer.
Read the original article

Tags:

Previous Article

(Curcumin + doxorubicin) by Immix BioPharma for Colorectal Cancer: Likelihood of...

Next Article

Enzalutamide by Pfizer for Fallopian Tube Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Nov 25, 2024

FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine 

FDA clears Novavax to resume trials of Covid-19 and flu...

Nov 13, 2024

Targovax announces plans to rebrand as Circio

Targovax announces plans to rebrand as Circio

Apr 20, 2023